Navigation Links
Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
Date:9/7/2009

ed to enter into another alliance with Ipsen. This collaboration is an opportunity to grow our pipeline in oncology, our area of expertise. We believe that Debio 0931 may have applications in the treatment of various types of cancer which will increase the quality of life of many cancer patients."

About the partnership

The collaboration between Ipsen and Debiopharm started in 1983 with regards to LHRH analogues, in particular for the triptorelin analogue Decapeptyl(R) (also known as Pamoreline(R) and Diphereline(R)). In October 2007, their partnership was extended to grant Ipsen access to future sustained-release formulations of Decapeptyl(R) developed by Debiopharm, among which a 6-month sustained release formulation that was filed in Europe in September 2008, for the treatment of locally advanced or metastatic prostate cancer. Decapeptyl(R) 1 and 3-month formulations are currently commercialised in more than 60 countries worldwide, including 25 in Europe and they have generated almost EUR 248million in sales in 2008.

About Ipsen

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty medicine, which is Ipsen's growth driver, in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partne
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
2. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
3. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Japanese Cancer Association and Debiopharm Honour Japanese Research
8. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
9. Debiopharm and EPFL Establish an Oncology Chair
10. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
11. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Shimadzu Scientific Instruments today announces the ... Offering wavelength scanning from 190 to 1,100 nm, ... in a variety of industries, including environmental, food ... enables intuitive operation, while the enhanced validation, maintenance ...
(Date:1/22/2015)... January 21, 2015 Cambridge Semantics, the leading ... today announced that 2014 was a record-breaking year across the ... of the Anzo Smart Data Platform and our Smart Data ... insights from diverse data which led to record growth for ...
(Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... , SEATTLE, Aug. 11 Omeros Corporation ... trial of OMS302, the Company,s ophthalmologic PharmacoSurgery(TM) product candidate. ... and an agent that causes pupil dilation (mydriasis), each ... Omeros, Phase 1/Phase 2 trial enrolled 61 ...
... QUEBEC CITY, Aug. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... focused on endocrinology and oncology, today reported financial and operating results ... 30, 2009. , , , Second Quarter ... poster presentations at the American Association of Cancer, ...
... ... at the Center for Orthopedics in Sheffield Village, Ohio, now offers OtisKnee® Custom Fit ... better implant fit and alignment -- and a faster return to an active lifestyle. ... Sheffield Village, ...
Cached Biology Technology:Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery 2AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 2AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 3AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 4AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 5AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 6AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 7AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 8William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 2William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 3William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 4
(Date:12/22/2014)... SHELTON, Conn. , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile commerce ... consultant, Apollo Robbins for the 2015 International CES ... Apollo Robbins will be at the NXT-ID booth ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... six billion base pairs from the genome of one person ... the J. Craig Venter Institute (JCVI), along with collaborators at ... of California San Diego (UCSD), have published a genome sequence ... chromosomes that were inherited from each parent. ...
... The immune response is actively turned on to target and ... it is just as important to turn the immune system ... fruit fly Drosophila has served as a good model for ... pathways and mechanisms. Recent work shows that the flys immune ...
... The earliest domesticated pigs in Europe, which many archaeologists ... actually introduced from the Middle East by Stone Age ... international team led by archaeologists at Durham University, which ... the National Academies of Sciences USA, analysed mitochondrial DNA ...
Cached Biology News:First individual genome sequence published 2First individual genome sequence published 3First individual genome sequence published 4Pig study sheds new light on the colonisation of Europe by early farmers 2
... of cytoplasmic granules, is a key ... leukocytes (e.g. basophils, neutrophils, eosinophils, and ... these secretory granules contain many proinflammatory ... many proteases (Hallgren, 2001). Tryptase, a ...
... DNA gel stain was developed specifically for reduced ... for staining DNA in agarose or acrylamide gels. ... than ethidium bromide but SYBR Safe stain's detection ... SYBR Safe stain comes as a premixed solution ...
... enables scientists who do not have access to ... have their biological samples tested for the concentration ... as 1-2-3 Chose the analytes you ... the S&S antibody menu. Send your samples ...
... nucleic acid gel stain is an exceptionally ... fluorescence when bound to dsDNA and low background ... in gels using laser scanners or standard UV ... also found uses in capillary electrophoresis, real-time PCR ...
Biology Products: